Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Risk factors for infection or colonization with CTX-M extended-spectrum-β-lactamase-positive Escherichia coli.

Han JH, Kasahara K, Edelstein PH, Bilker WB, Lautenbach E.

Antimicrob Agents Chemother. 2012 Nov;56(11):5575-80. doi: 10.1128/AAC.01136-12. Epub 2012 Aug 13.

2.

Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge.

Rodríguez-Baño J, Navarro MD, Romero L, Muniain MA, de Cueto M, Ríos MJ, Hernández JR, Pascual A.

Clin Infect Dis. 2006 Dec 1;43(11):1407-14. Epub 2006 Oct 25.

3.

Antimicrobial susceptibility of well-characterised multiresistant CTX-M-producing Escherichia coli: failure of automated systems to detect resistance to piperacillin/tazobactam.

Pitout JD, Le P, Church DL, Gregson DB, Laupland KB.

Int J Antimicrob Agents. 2008 Oct;32(4):333-8. doi: 10.1016/j.ijantimicag.2008.04.023. Epub 2008 Aug 12.

PMID:
18701262
5.

Clinical and molecular epidemiology of community-onset, extended-spectrum beta-lactamase-producing Escherichia coli infections in Thailand: a case-case-control study.

Apisarnthanarak A, Kiratisin P, Saifon P, Kitphati R, Dejsirilert S, Mundy LM.

Am J Infect Control. 2007 Nov;35(9):606-12.

PMID:
17980240
6.

Characterization of Piperacillin/Tazobactam-Resistant Klebsiella oxytoca Recovered from a Nosocomial Outbreak.

Fujita A, Kimura K, Yokoyama S, Jin W, Wachino J, Yamada K, Suematsu H, Yamagishi Y, Mikamo H, Arakawa Y.

PLoS One. 2015 Nov 5;10(11):e0142366. doi: 10.1371/journal.pone.0142366. eCollection 2015.

7.

Comparison of the risk of acquiring in vitro resistance to doripenem and tazobactam/piperacillin by CTX-M-15-producing Escherichia coli.

Horiyama T, Kanazawa S, Hara T, Izawa M, Sato T, Yamaguchi T, Tsuji M, Maki H.

J Infect Chemother. 2015 May;21(5):381-4. doi: 10.1016/j.jiac.2015.01.006. Epub 2015 Jan 23.

PMID:
25662788
8.

Efficacy of a Ceftazidime-Avibactam combination in a murine model of Septicemia caused by Enterobacteriaceae species producing ampc or extended-spectrum β-lactamases.

Levasseur P, Girard AM, Lavallade L, Miossec C, Pace J, Coleman K.

Antimicrob Agents Chemother. 2014 Nov;58(11):6490-5. doi: 10.1128/AAC.03579-14. Epub 2014 Aug 18.

9.

In the literature. Piperacillin-tazobactam and extended-spectrum β-lactamase--producing Escherichia coli.

[No authors listed]

Clin Infect Dis. 2013 Nov;57(10):iii-iv. No abstract available.

PMID:
24308040
10.

Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli.

Seo YB, Lee J, Kim YK, Lee SS, Lee JA, Kim HY, Uh Y, Kim HS, Song W.

BMC Infect Dis. 2017 Jun 7;17(1):404. doi: 10.1186/s12879-017-2502-x.

11.

[Replacement of third-generation cephalosporins by piperacillin-tazobactam decreases colonization of extended-spectrum beta-lactamases-producing intestinal Escherichia coli].

Zhao ZM, Chu YZ, Wan JH, Bai YL, Zhang JP, Li JB, Wang X, Wang Q, Li LY, Chen BY.

Zhonghua Nei Ke Za Zhi. 2007 Sep;46(9):714-7. Chinese.

PMID:
18028795
12.

Cephalosporin and fluoroquinolone combinations are highly associated with CTX-M β-lactamase-producing Escherichia coli: a case-control study in a French teaching hospital.

Cassier P, Lallechère S, Aho S, Astruc K, Neuwirth C, Piroth L, Chavanet P.

Clin Microbiol Infect. 2011 Nov;17(11):1746-51. doi: 10.1111/j.1469-0691.2010.03349.x. Epub 2011 Apr 12.

13.

Prevalence and characteristics of fecal antimicrobial-resistant Escherichia coli in a cohort of Japanese men undergoing prostate biopsy.

Kamei J, Yagihara Y, Kume H, Horiuchi T, Sato T, Nakagawa T, Fujimura T, Fukuhara H, Moriya K, Homma Y.

Int J Urol. 2017 Apr;24(4):295-300. doi: 10.1111/iju.13308. Epub 2017 Feb 21.

14.

Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model.

Docobo-Pérez F, López-Cerero L, López-Rojas R, Egea P, Domínguez-Herrera J, Rodríguez-Baño J, Pascual A, Pachón J.

Antimicrob Agents Chemother. 2013 May;57(5):2109-13. doi: 10.1128/AAC.02190-12. Epub 2013 Feb 25.

15.

In vitro selection of variants resistant to beta-lactams plus beta-lactamase inhibitors in CTX-M beta-lactamases: predicting the in vivo scenario?

Ripoll A, Baquero F, Novais A, Rodríguez-Domínguez MJ, Turrientes MC, Cantón R, Galán JC.

Antimicrob Agents Chemother. 2011 Oct;55(10):4530-6. doi: 10.1128/AAC.00178-11. Epub 2011 Jul 25.

16.

Epidemiology and risk factors for isolation of Escherichia coli producing CTX-M-type extended-spectrum β-lactamase in a large U.S. Medical Center.

Hayakawa K, Gattu S, Marchaim D, Bhargava A, Palla M, Alshabani K, Gudur UM, Pulluru H, Bathina P, Sundaragiri PR, Sarkar M, Kakarlapudi H, Ramasamy B, Nanjireddy P, Mohin S, Dasagi M, Datla S, Kuchipudi V, Reddy S, Shahani S, Upputuri V, Marrey S, Gannamani V, Madhanagopal N, Annangi S, Sudha B, Muppavarapu KS, Moshos JA, Lephart PR, Pogue JM, Bush K, Kaye KS.

Antimicrob Agents Chemother. 2013 Aug;57(8):4010-8. doi: 10.1128/AAC.02516-12. Epub 2013 Jun 10.

17.

Risk factors and molecular epidemiology of community-onset, multidrug resistance extended-spectrum β-lactamase-producing Escherichia coli infections.

Park SY, Kang CI, Wi YM, Chung DR, Peck KR, Lee NY, Song JH.

Korean J Intern Med. 2017 Jan;32(1):146-157. doi: 10.3904/kjim.2015.113. Epub 2016 Apr 20.

18.

Risk factors associated with the community-acquired colonization of extended-spectrum beta-lactamase (ESBL) positive Escherichia Coli. an exploratory case-control study.

Leistner R, Meyer E, Gastmeier P, Pfeifer Y, Eller C, Dem P, Schwab F.

PLoS One. 2013 Sep 11;8(9):e74323. doi: 10.1371/journal.pone.0074323. eCollection 2013.

19.

CTX-M-190, a Novel β-Lactamase Resistant to Tazobactam and Sulbactam, Identified in an Escherichia coli Clinical Isolate.

Shen Z, Ding B, Bi Y, Wu S, Xu S, Xu X, Guo Q, Wang M.

Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e01848-16. doi: 10.1128/AAC.01848-16. Print 2017 Jan.

20.

Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.

López-Cerero L, Picón E, Morillo C, Hernández JR, Docobo F, Pachón J, Rodríguez-Baño J, Pascual A.

Clin Microbiol Infect. 2010 Feb;16(2):132-6. doi: 10.1111/j.1469-0691.2009.02893.x. Epub 2009 Jul 15.

Supplemental Content

Support Center